These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24598833)

  • 1. Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity.
    López-Torres E; Süveges A; Peñas-LLedó EM; Doña A; Dorado P; LLerena A; Berecz R
    Drug Metabol Drug Interact; 2014; 29(2):123-6. PubMed ID: 24598833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Disorder of liver functions in a schizophrenic patient after long-term risperidone treatment--case report].
    Radzik J; Grotthus B; Leszek J
    Psychiatr Pol; 2005; 39(2):309-13. PubMed ID: 15881625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
    Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
    J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment.
    Bozina N; Jovanović N; Lovrić M; Medved V
    Ther Drug Monit; 2008 Dec; 30(6):748-51. PubMed ID: 18806696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey.
    Erdogan A; Karaman MG; Ozdemir E; Yurteri N; Tufan AE; Kurcer MA
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):407-13. PubMed ID: 20973711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute cholestatic hepatitis probably associated with risperidone.
    Llinares Tello F; Hernández Prats C; Bosacoma Ros N; Pérez Martínez E; Climent Grana E; Navarro Polo JN; Ordovás Baines JP
    Int J Psychiatry Med; 2005; 35(2):199-205. PubMed ID: 16240976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatic tolerance of atypical antipsychotic drugs].
    Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case study: risperidone-induced hepatotoxicity in pediatric patients.
    Kumra S; Herion D; Jacobsen LK; Briguglia C; Grothe D
    J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):701-5. PubMed ID: 9136506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission of drug-induced hepatitis after switching from risperidone to paliperidone.
    Paulzen M; Orfanos S; Gründer G
    Am J Psychiatry; 2010 Mar; 167(3):351-2. PubMed ID: 20194492
    [No Abstract]   [Full Text] [Related]  

  • 11. Risperidone-induced cholestatic hepatitis.
    Krebs S; Dormann H; Muth-Selbach U; Hahn EG; Brune K; Schneider HT
    Eur J Gastroenterol Hepatol; 2001 Jan; 13(1):67-9. PubMed ID: 11204814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
    de Leon J; Susce MT; Pan RM; Fairchild M; Koch WH; Wedlund PJ
    J Clin Psychiatry; 2005 Jan; 66(1):15-27. PubMed ID: 15669884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
    Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
    Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
    Hendset M; Molden E; Knape M; Hermann M
    Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
    Bork JA; Rogers T; Wedlund PJ; de Leon J
    J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of clinical response to risperidone.
    Llerena A; Berecz R; Peñas-Lledó E; Süveges A; Fariñas H
    Pharmacogenomics; 2013 Jan; 14(2):177-94. PubMed ID: 23327578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone-induced hepatotoxicity?
    Geller WK; Zuiderwijk PB
    J Am Acad Child Adolesc Psychiatry; 1998 Mar; 37(3):246-7. PubMed ID: 9519624
    [No Abstract]   [Full Text] [Related]  

  • 18. Risperidone-induced hepatotoxicity.
    Benazzi F
    Pharmacopsychiatry; 1998 Nov; 31(6):241. PubMed ID: 9930641
    [No Abstract]   [Full Text] [Related]  

  • 19. [Follow-up of a 16-year-old adolescent with early-onset schizophrenia and catatonic symptoms].
    Menard ML; Yagoubi F; Drici M; Lavrut T; Askenazy F
    Encephale; 2013 May; 39 Suppl 1():S29-35. PubMed ID: 23219595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
    Roke Y; van Harten PN; Franke B; Galesloot TE; Boot AM; Buitelaar JK
    Pharmacogenet Genomics; 2013 Sep; 23(9):487-93. PubMed ID: 23851570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.